Cargando…
Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer
For patients with unresectable locally-advanced non-small cell lung cancer (LA-NSCLC), concurrent chemoradiotherapy improves overall survival as compared to sequential chemotherapy and radiation therapy, but is associated with higher rates of toxicities. Acute, clinically significant esophagitis or...
Autores principales: | Verma, Vivek, Simone, Charles B., Werner-Wasik, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615335/ https://www.ncbi.nlm.nih.gov/pubmed/28885561 http://dx.doi.org/10.3390/cancers9090120 |
Ejemplares similares
-
Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
por: Abe, Takanori, et al.
Publicado: (2020) -
Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer
por: Katayama, H, et al.
Publicado: (2004) -
A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer
por: Zheng, Qiangqiang, et al.
Publicado: (2022) -
Comparison of Induction Chemotherapy Plus Concurrent
Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced
Nasopharyngeal Carcinoma
por: Xu, Guoqiang, et al.
Publicado: (2021) -
Prediction of response by FDG PET early during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer
por: Kim, Suzy, et al.
Publicado: (2014)